𝔖 Bobbio Scriptorium
✦   LIBER   ✦

559 Combined pegylated interferon α-2a and ribavirin in treatment of chronic hepatitis C in Egypt (ANRS 1211 Trial)

Book ID
117374066
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
126 KB
Volume
42
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neutralizing antibodies to interferon-α
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)
✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐

Randomized controlled trial of pegylated
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu